Altamira Therapeutics to effect 20-for-1 reverse stock split

Thanks to its improved equity position, on November 21, 2023 Altamira regained compliance with the minimum equity requirements for continued listing on Nasdaq. Further, the Companys Board of Directors has decided to effect a 20-for-1 reverse stock split on December 13, 2023. This measure shall ensure Altamiras timely compliance also with Nasdaqs one-dollar minimum bid price listing rule and make the stock more attractive for institutional investors. Altamira anticipates meeting the Nasdaq requirements before the close of 2023.